Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo procedure aims to seal aortic tears more completely

NCT ID NCT07198295

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to treat a tear in the aorta (the body's main artery) called type B aortic dissection. The standard repair often leaves small leaks that can cause the artery to widen over time. The new procedure adds a second step: placing small plugs in the false channel to block blood flow and encourage healing. Researchers will follow 72 patients for one year to see if the false channel closes completely and to check for serious complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stent-graft and vascular plugs
What this could lead to
If successful, this combined procedure could become a new standard to improve long-term outcomes for type B aortic dissection by promoting complete aortic healing.
What could go wrong
This is an early-stage observational study with only 72 participants, so results may not apply broadly. The procedure carries risks like stroke, kidney injury, or paralysis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll adult patients (aged 18-80 years) diagnosed with acute or subacute uncomplicated type B aortic dissection (TBAD). Participants must exhibit typical clinical and radiological features of TBAD, with distal extension of the dissection to the infrarenal abdominal aorta. All patients are scheduled to undergo elective thoracic endovascular aortic repair (TEVAR) combined with false lumen embolization using vascular plugs. The population excludes individuals requiring emergency intervention, those with complicated dissections (e.g., malperfusion, rupture, or refractory pain), previous aortic surgery, trauma- or infection-related etiologies, significant uncontrolled comorbidities, recent major cardiovascular events, or contraindications to the endovascular procedure. The study aims to include a representative sample suitable for evaluating the safety and efficacy of TEAVR with false lumen embolization under real-world clinical conditions.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Patients must meet all of the following conditions to be enrolled: 1. Diagnosed with acute or subacute (symptom onset ≤30 days) Stanford type B aortic dissection. 2. Present with typical clinical symptoms and imaging-confirmed aortic dissection. 3. Dissection extends distally to involve the infrarenal abdominal aorta. 4. Scheduled to undergo elective TEVAR combined with false lumen embolization. Exclusion Criteria Patients will be excluded if they meet any of the following conditions: 1. Requiring emergency surgery due to rupture, impending rupture, or severe malperfusion. 2. Complicated type B dissection (e.g., visceral/limb ischemia, refractory pain, or hemodynamic instability). 3. Suspected traumatic or infectious etiology of the dissection. 4. Previous history of aortic surgery or endovascular repair. 5. Use of alternative techniques during the procedure (e.g., PETTICOAT, long-segment coverage). 6. Uncontrolled systemic diseases (e.g., severe cardiac/pulmonary/hepatic dysfunction, advanced malignancy, cachexia, or uncorrectable coagulation disorders). 7. Myocardial infarction or stroke within the past 6 months. 8. Age \<18 years or \>80 years. 9. Patient refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic dissection type B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.